10-K · March 9, 2026
Editas pivoted from ex vivo commercialization to an in vivo-focused strategy, nominating EDIT-401 in September 2025 as its lead in vivo candidate and targeting an IND submission by mid-2026 with early human…
Earnings analysis · 10-Q
EDIT earnings analysis
Filed May 5, 2026 · Our reading of the company's report
The latest report
Editas Medicine reported a significant decline in revenue and a net loss improvement in Q1 of 2026, marking a loss of $24.98 million, or $0.26 per share, down from $76.09 million, or $0.92 per share in the same quarter…
Read full summary
Editas Medicine reported a significant decline in revenue and a net loss improvement in Q1 of 2026, marking a loss of $24.98 million, or $0.26 per share, down from $76.09 million, or $0.92 per share in the same quarter last year. Revenue dropped drastically to $2.83 million, driven by the conclusion of a collaboration agreement, while cash reserves dipped to $123.6 million, affirming sufficient funds to support operations until Q3 2027.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.26
What stood out
-
Improved EPS Figures
EPS improved to -$0.26 vs. -$0.92 from last year, a 72% reduction in losses.
-
Reduced Operating Expenses
Total operating expenses fell to $27.83 million, a decrease of 66% from $80.82 million in the prior year.
-
Improved R&D Cost Efficiency
Research and development expenses decreased by $8.99 million to $17.6 million, a 34% reduction year-on-year.
-
Cash Reserves Sufficient to Fund Operations
Cash and cash equivalents stood at $123.6 million, expected to last until Q3 2027.
-
No Restructuring Charges
No restructuring and impairment charges incurred, a significant drop from $40.85 million in the prior year.
-
Collaboration Income From Vertex
Ongoing revenues anticipated from Vertex, with $10 million received in license fees this quarter.
What to watch
-
Heavily Dependent on Licensing Revenues
The majority of revenue generated from Vertex License Agreement leads to uncertainty due to lack of product sales.
-
Increased Costs with Future Development
Future clinical development costs for EDIT-401 may rise significantly without assured funding.
-
Patent Rulings Affecting Intellectual Property
Ongoing legal disputes regarding patent validity and ownership may impact business operations.
Management's outlook
No explicit forward guidance provided in this quarterly report.
Earlier filings 4
10-Q · November 10, 2025
Editas Medicine reported significant improvements in Q3 2025, showcasing a stunning revenue increase to $7.543 million from just $61 thousand in Q3 2024, marking a substantial year-over-year rise. The company's net loss…
10-Q · August 12, 2025
Editas reported Q2 collaboration revenue of $3.578M (vs. $0.513M a year ago) and GAAP net loss of $53.235M (-$0.63/share). Revenue improved materially year-over-year but declined sequentially vs. Q1 2025; operating loss…
10-Q · May 8, 2024
Editas reported collaboration revenue of $1.135 million and a net loss of $61.95 million (EPS $(0.76)) for the quarter ended March 31, 2024. Revenue collapsed versus the year-ago quarter ($9.851 million) while operating…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.